Equity Overview
Price & Market Data
Price: $1.34
Daily Change: +$0.005 / 0.37%
Range: $1.29 - $1.39
Market Cap: $154,612,256
Volume: 733,989
Performance Metrics
1 Week: 29.52%
1 Month: 50.66%
3 Months: 1.49%
6 Months: -56.83%
1 Year: -71.55%
YTD: -17.58%
Company Details
Employees: 181
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.